Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe
Hologic, Inc. (Nasdaq: HOLX) today announced its broad European launch of the Novodiag® system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021 and will bring the benefits of the Novodiag system to a broader range of customers in Europe.
The Novodiag system combines real-time PCR and microarray capabilities. This enables multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing. Its CE-IVD test menu includes highly multiplexed on-demand assays detecting gastrointestinal infections and antibiotic resistance, as well as a targeted assay for the detection of SARS-CoV-2. A strong pipeline is also in development.
“Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With the Hologic launch of the Novodiag system, we are delivering against this goal,” said Jan Verstreken, Group President, International at Hologic. “The addition of the Novodiag system to our diagnostic molecular scalable solutions portfolio will offer more customers in Europe a wider choice of solutions that meet their needs, from single patient rapid testing to population-level screening.”
Hologic’s current diagnostic offering is anchored by the Panther® System, a best-in-class, fully automated, sample-to-result platform designed to be used across laboratories of varying throughputs. The Novodiag system is a high multiplex technology that is precision-engineered for simplicity, accuracy and affordability across a broad and growing menu of high- and low-plex assays. It complements the Panther System, along with Panther Scalable Solutions, and expands Hologic’s offering, allowing the Company to meet customers’ growing diagnostic testing needs from small to the largest laboratories.
Tuomas Tenkanen, CEO, Mobidiag, a Hologic company said, “Mobidiag is already realizing the benefits of being part of the Hologic family, and today’s launch will allow Novodiag to reach a far broader customer market faster, delivering the benefits of an on-demand system that offers ease of use, high multiplex capability and a rapid turnaround time.”
For more information visit https://www.hologic.com/hologic-products/novodiag-system.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, Mobidiag, Novodiag, Panther and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about launching the Novodiag system and related assays. There can be no assurance that these products will achieve the benefits described herein, that they will be commercially successful or achieve any expected level of sales, or that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
SOURCE: Hologic, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005411/en/
Contact information
Hologic
Investor Contact:
Michael Watts
+1 858.410.8588
michael.watts@hologic.com
Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“ All Genetic Diseases Could be Cured within a Decade ” , Hears Dubai Future Forum20.11.2025 15:15:00 EET | Press release
All known genetic diseases could be cured within the next decade thanks to major advances in gene editing, a leading scientist told the Dubai Future Forum 2025. Discussing his company’s research, Dr. Trevor Martin, Co-founder and CEO of Mammoth Biosciences, described “a one-time cure that will reshape the healthcare system as we know it.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120548681/en/ Dubai Future Forum 2025 (Photo: AETOSWire) Opening the forum, Khalfan Belhoul, CEO of Dubai Future Foundation, introduced the concept of “national cognitive potential”, arguing that countries in the future will gain a competitive edge in fields like AI by leveraging the collective cognitive strength of their societies. In another session, Dr. Nikku Madhusudhan, Professor of Astrophysics at the University of Cambridge, said there is a “good chance” humanity will discover life on another planet—possibly in the next decade. He exp
Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies20.11.2025 15:00:00 EET | Press release
Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies. Cassidy Bio’s AI-driven genomic foundation model combines proprietary wet-lab data, population-scale genomic insights, and advanced machine learning to predict the best pairings of guides, enzymes, and delivery modalities, matching them to optimal therapeutic contexts. This creates a scalable capability that supports an end-to-end workflow for genome editing at scale. By moving from siloed trial-and-error to a holistic, predictive approach, Cassidy aims to accelerate the discovery and development of safer, more reliable genetic medicines. “The promise of genome editing will
12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity20.11.2025 15:00:00 EET | Press release
How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/ Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers. The new face of fraud The identity threat landscape has entered a new industrial phase, defined by three structural shifts: Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own. Frau
Scientist.com Completes Acquisition by GHO Capital Partners to Accelerate Global R&D Orchestration20.11.2025 14:55:00 EET | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform, and GHO Capital Partners LLP (“GHO”), the specialist private equity investor in global healthcare, today announced the successful closing of GHO’s acquisition of Scientist.com. The transaction marks the beginning of an accelerated expansion phase, strengthening Scientist.com’s mission to transform pharmaceutical R&D by streamlining the entire outsourced research lifecycle. “This is a pivotal moment for Scientist.com and for the global research community we support,” said Kevin Lustig, CEO and Chris Petersen, CTO, the founders of Scientist.com. “Partnering with GHO, a team that shares our vision and brings deep expertise in scaling healthcare technology companies, enables us to invest aggressively in our AI-powered orchestration platform and expand our global footprint. Together, we are better positioned than ever to meet growing demand for faster, smarter and more compliant research sourcing.” Fo
SimpliStor™ Solid State Data Recorder Delivers High-Speed, Radiation-Tolerant Storage for Next-Generation Space Missions20.11.2025 14:00:00 EET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the SimpliStor™ Solid State Data Recorder (SSDR), a next-generation, radiation-tolerant data recorder that gives satellite operators, system integrators, and spacecraft designers a faster, smarter, and more resilient way to capture and protect mission-critical information in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120514203/en/ Frontgrade's SimpiStor™ 2.5TB Solid-State Data Recorder High-Throughput Performance SimpliStor delivers 2.5 terabytes of storage and 10Gbps throughput in a compact 3U SpaceVPX package, combining exceptional performance with low power consumption. Users can record more data in less time, with latency under 100 microseconds and continuous “store-to-full” recording, ensuring no data loss during peak operations. A 33-minute continuo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom